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Introduction
Sickle cell disease (SCD) is caused by a single nucleotide substitution (GAG to GTG) due to a point mutation in the β-globin gene, which results in a substitution change replacing amino acid glutamic acid with valine at the sixth position of the beta globin chain thus resulting in the production of the sickle hemoglobin (HbS) (Randolph et al. 2012 ). Individuals having both the β-globin gene allele mutated are called homozygous (HbSS) and show various symptoms of SCD whereas those with a single mutated β-globin gene are known as sickle cell trait (HbSA) or carriers and are asymptomatic. The oxyhemoglobin dissociation curve is right shifted in SCD patients indicating a lower affinity of the sickle hemoglobin for oxygen (Abdu et al. 2008) . Reduced oxygen tension causes polymerization of this mutated form of hemoglobin, thus changing the shape of the red blood cells (RBC) to a sickle shape, which thereby results in development of chronic anemia, acute painful crisis that arises due to blockage of small vessels. Progressive damage to multiple organs sets in over time that includes damage to brain, kidneys, lungs, bones and cardiovascular system (Rees et al. 2010 ).
Around 14 million individuals are affected by SCD worldwide, where as in the United
States alone 80,000-100,000 people primarily African Americans have this disease (Brousseau et al. 2010; Alapan et al. 2016) . Annually, the overall healthcare cost of SCD in US alone is estimated to be over $1 billion. (Ballas et al. 2009 ).
Like any hereditary disease, attempts to prevent its occurrence are the best approaches against SCD. The first level of prevention is known as prenatal diagnosis (PND), which makes parents who are homozygous for SCD be aware of the risk of having a child with SCD. People living in the remote areas and in developing nations are not aware of the risk of having a child born with SCD due to the lack of information and appropriate diagnostic tools. Also, the second level of prevention is neonatal screening. Mortality due to infection and stroke is very common in newborns that are not diagnosed for SCD, which happens when newborns are not screened for the presence of sickle hemoglobin in the blood.
Studies have shown that there is a greater risk of Streptococcus pneumonia infection in children up to 3 years of age. The mortality rate in these children is as high as 30% (Yanni et al. 2009 ). Hence, it is essential to carry out neonatal screening for SCD so that proper management can be delivered to reduce newborn mortality rates. This problem is acute in developing countries where early diagnosis is not very prevalent and hence a relatively higher number of newborn mortality due to sickle cell disease is observed in these nations.
Developed nations rely on molecular and protein-based tests to diagnose SCD.
Molecular tests are expensive and thus not a practical approach in underdeveloped countries. In African countries for instance, screening attempts have been unsuccessful mostly due to the high cost of screening kits available in the market (Hajer et al. 2012 ).
In addition to the cost issue, other challenges faced by healthcare professional include the heterogeneities among SCD patients and the multiple organs effected in this disease.
This review describes various SCD screening and monitoring methodologies. It also discusses the challenges involved with such technologies and future of SCD screening.
The review also describes low cost techniques that can be implemented in developing nations to detect SCD cases in children at an early stage with significant lower costs. In the sickling test, polymerization of sickle hemoglobin is induced by sodium metabisulfite followed by sickling of the RBC by reducing oxygen tension. This test is not considered as an optimal test to differentiate between SCD from SCT because it has the potential to cause confusion between them. Also, other tests, that can positively identify the homozygote from heterozygote are available (Tubman et al. 2015) . Other clinically significant forms of sickle hemoglobinopathies that include HbC and β-thalassemia cannot be detected in this test (Fabry et al. 2003) .
In order to determine the type of hemoglobin present, (SCA vs SCT), additional tests need to be carried out, which include the following: hemoglobin electrophoresis, high performance liquid chromatography (HPLC), isoelectric focusing (IEF), and DNA based analysis (Greene et al. 2015) . The basic principle upon which electrophoresisbased techniques operate is that different types of hemoglobin molecules carry different charges on them and hence they migrate at different velocities in an electrophoresis gel when an electric current is applied. Each of the above mentioned are explained in detail below.
Hemoglobin electrophoresis:
Unaffected individual has the following proportions of hemoglobins -HbA= >95%; (95-98%); HbA2 = 1.5-3.7%; HbF=<2%;( 0.8-2%); HbS =0%; HbC =0% and Newborn HbF = 50-80%. Hemoglobin electrophoresis is a method used to discriminate between these different types of hemoglobin under alkaline conditions using variety of sieving materials that includes gel and paper. Under alkaline condition various forms of hemoglobin have a net negative charge and move towards the positive electrode. For high-throughput screening a capillary zone electrophoresis (CZE) is carried out in a U-shaped narrow-bore fused-silica capillary tube. Like HPLC, CZE is an automated method and has been shown in various studies to be an effective methodology to detect monoclonal gammopathies and protein abnormalities present in the serum. Migration in CZE is similar to conventional electrophoretic methods in which the protein migrates based on its net charge when an electric field in applied. The buffers used in CZE differ from gel electrophoresis where barbital buffer is used. Barbital buffer has a disadvantage since it has a high absorbance at 200nm wavelength, which coincides with peptide bonds and thus interferes with the detection system. To avoid this CZE uses borate-based buffers that do not cause the above interference (Dolník et al. 1995) .
The negative charge of the fused silica used to make the capillaries provides a negative surface charge to the migrating protein molecules. Also, the narrow lumen (about 50μm in diameter) inside the capillary tubes makes the surface area relatively large. This combined effect of large surface area and charge on the capillaries causes a more effective movement of proteins in the sample towards the cathode than could have been achieved by only voltage difference between cathode and anode. This high charge and surface area offered by the capillaries causes a higher resolution of the hemoglobin variants present in the samples. A detector is usually present at the cathodal end of the capillary, which records the optical density at a wavelength of 200nm (peptide bond absorption) as the proteins migrate past it. The Hb variants pass by the detector in the following order-γ, β, α2, and α1 globulins (Keren et al. 1998 ).
High resolution, ease of automation, shorter run time at a high voltage and no additional requirement for densitometer are the advantages of the CZE methodology for diagnosis of SCD. However, CZE is a new technology and the limitations haven't been properly investigated so far. One major drawback is this methodology does not have any gel that can be examined. The bands represent those substances that have absorbency at around 200 nm, which are usually proteins. Non-protein substances having similar absorbency parameters can therefore also produce bands that can be confused with hemoglobin variants (Keren et al. 1998 ; Bain, B. J. 2008). CZE requires a detector, which records optical density at a wavelength of 200nm and this is connected to a computer for data acquisition and also needs high voltage power supply. All these arrangements are expensive and are not readily available in remote areas hence CZE-based SCD screening methodology is not easy to implement in developing or in underdeveloped countries.
Isoelectric focusing (IEF):
Every protein carries a net charge that varies according to the pH of the surrounding environment. An isoelectric point (pI) is defined as a point in pH gradient where a protein carries a net zero charge. Hemoglobin samples are run in a gel medium across which an electrical gradient is applied, and a fixed pH gradient is maintained throughout the gel ( In a pilot study conducted in Tunisia, a low cost neonatal screening method using IEF assay for the detection of SCD and other Hb variants has been reported (Hajer et al. 2012) . In this study samples from 9148 newborns were collected on blotting paper (Whatman grade BFC 180) at maternity centers and using a general office-use printer these blotting papers were printed. IEF methodology was then carried out by a labprepared agarose gel to test the dried blood samples from these newborns. This low cost IEF on lab prepared agarose gel along with office printer printed blotting paper for sample collection proved to be an effective method since this method successfully detected the newborns who had abnormal Hbs (HbS, HbC, HbO and HbG). The accuracy of the data collected in this screening method was also verified by comparing with previously established national data. The families of these newborns were made aware of the result and guidelines for treatment along with genetic counseling was also provided. 
High Performance Liquid Chromatography (HPLC):
Cation exchange HPLC uses charge to separate different types of hemoglobin in the blood. HPLC has a negatively charged stationary phase comprising of an absorbent material that can be either silica or other polymers. The mobile phase is a liquid with an increasing concentration of cations that passes through the chromatography column. HU is the drug-of-choice to reduce the pain episode frequency in sickle cell patients.
HU raises the level of HbF that significantly decreases the rate of painful episodes by about 50% (Agrawal et al. 2014 ). Blood transfusion lowers the amount of sickle hemoglobin in the body. Since the normal red blood cells increase in the blood stream thus increasing the supply of oxygen.
Liquid Chromatography-Mass spectrometry (LC-MS/MS):
It is important to also include liquid chromatography-mass spectrometry (LC-MS/MS) (also known as tandem mass spectrometry) under this category since it is a much faster and accurate and can be used for cost effective population of screening of sickle cell disease (Chace et al. 2003) . For characterization of hemoglobinopathies Electrospray ionization in conjunction with tandem MS have been used. Masses of intact globin chains can be measured by scanning whole blood. This is followed by tryptic digestion of the blood specimen for detailed peptide analysis in order to specify the hemoglobin variant in the blood. This method allows unambiguous characterization of majority of globin mutations (Daniel et al. 2005 ).
DNA Analysis:
DNA based assays can be used to screen patients by looking for mutations in the β-globin gene that results in the production of the sickle hemoglobin (Clark et al. 2004 ).
Compared to the methodologies discussed earlier, DNA analysis to screen SCD is usually more expensive. There are two ways DNA analysis can be performed. One popular method, known as Restriction Fragment Length Polymorphism (RFLP), looks for Ddel I restriction enzyme site in the β-globin gene. Mutation that causes SCD eliminates this restriction site. Thus, normal DNA without sickle mutation will be cut with Ddel I whereas DNA having mutation for SCD will not be cut with this enzyme.
To carry out this procedure first DNA sample from individuals are collected and a 125 bp region of the β-globin gene is PCR amplified using gene-specific primers and this amplified DNA is then subjected to digestion by Ddel I. After incubation with the restriction enzyme for a certain time, an aliquot of this reaction is loaded in a gel and electrophoresis is carried out. Individuals with mutation in the β-globin gene will have one big fragment (125 bp) whereas normal DNA will be cut into two fragments by the RFLP is easy to perform and analyze and is an inexpensive method compared to other molecular techniques. However, the drawback of RFLP method is it's a low throughput method since most of the steps need to be performed manually. It's the method adopted in laboratories handling fewer samples.
Clinicians and researchers also use other DNA analysis methods that include wholeexome sequencing (WES) to identify pathogenic single-nucleotide variants (SNVs). This is achieved by sequencing only the protein-coding portions of the β-globin gene followed by copy number variation analysis of the beta globin locus to determine normal vs. sickle mutation. These sequencing methods provide the most accurate and comprehensive report of the beta-globin gene. However, the cost involved is much higher than other methodologies used to screen SCD.
SCD Diagnosis by using emerging Point-of-care (POC) methodologies:
The idea behind recent methodologies is to make SCD screening accessible by adapting to technologies that are available at the POC even in the most developing nations. The emerging technologies consider the cost of a particular methodology, complexity of use, accessibility and availability of trained personnel. The emerging technologies in the past few years have thus been categorized into four groups: (a) paper-based hemoglobin solubility assays, (b) lateral flow immunoassays, (c) density-based separation, and (d) micro engineered electrophoresis. Each of these methodologies has been explained in detail below.
Paper-based Hemoglobin Solubility Assay:
The principle behind this technology is the insoluble property of hemoglobin and the filtration ability of paper. This assay uses a microfluidic paper-based device known as μPADs, to analyze the samples. In this way the HbS in the sample can be seen with our eyes. A drop of blood (~20μL) is mixed with hemoglobin solubility buffer in a 1:10 ratio and then put onto a chromatography paper that is patterned (Fig. 2) . Based on the different capillary action pattern of different hemoglobin types, various bloodstain patterns are observed for HbS that is polymerized and other hemoglobin types (Shevkoplyas et al. 2017) . Screening can be achieved within 20 minutes and the method is 94.2% sensitive (see Table 1 below) (Yang et al. 2013 ). The advantage of this paperbased is that it is cheaper compared to other methods, easy to interpret and sample preparation is very easy. Individual tests can be performed without the need to batch samples.
The technique however suffers from few disadvantages. First, if the blood clots before adding to the μPAD, then the capillary action of the blood is lost, and the blood would not be absorbed in the paper. The interpretation depends on naked eye detection and hence the assay is completely operator based and thus prone to error. To minimize error an automated image-processing algorithm can be paired with this assay. The assay cannot distinguish between the hemoglobin types HbSC and HbAS. Newborns have high percentage of HbF which may hinder the polymerization of HbS and thus this test has limited application in terms of newborn screening (Mulumba et al. 2015) . (Fig. 3B) .
One microliter of blood is diluted to 1mL with distilled water followed by addition of 15μL of this diluted blood to the sample pad. This is then immersed in a 150μL assay buffer solution containing red-colored colloidal gold nanoparticles and the solution is allowed to be absorbed in the strip for 10 minutes before taking the strip out of the solution. The test strip is then visually detected for the line on the strip where the antibodies are deposited, which indicates the presence of the specific hemoglobin type.
It takes around 20 minutes to obtain result by this assay (Quinn et al .2016 ). The
HemoTypeSC assay achieved 100% sensitivity and at the same time had a low operating cost. The assay was able to distinguish between HbAA, HbAS, HbAC, HbSS, HbSC, and HbCC but it could not detect HbF and HbA2 Hb types. 
Density-Based Separation:
This technique uses the difference in cell densities to separate SCD cells from normal Five microliters of blood are mixed with aqueous polymeric solution and then loaded into capillary tubes (Fig. 4) . The tubes are then centrifuged for 10 minutes that causes dense RBC of SCD patients to settle. This method has several limitations that include the higher cost due to inclusion of the centrifugation step. Centrifugation also makes it difficult to conduct this test at POC settings. Besides samples need to be run in batches increasing the turnaround time. Density based separation method cannot differentiate between HbAA and HbAS. Also, newborn screening is not possible with this method due to the presence of high % of HbF that restricts the occurrence of dense RBC. Other factors like medication, health conditions, treatment processes and genetic factors affect the density of RBC and hence the outcome of test result of this assay (see Table 1 below). 
Micro engineered Electrophoresis:
Micro engineered electrophoresis (HemeChip) is a SCD screening method recently developed and can be used to differentiate between HbA, HbA2, HbS, HbF and HbC.
The HemeChip device consists of a cellulose acetate paper for electrophoresis that is housed in a microfabricated Polymethyl Methacrylate (PMMA) chamber. An electric field is applied, and the types of hemoglobin are separated. An application software that can be downloaded and used in the mobile phone for image processing purpose at the POC has also been developed (Fig. 5 ). This software is used to quantitate the hemoglobin amount in the HemeChip (Ung et al. 2015) .
Less than 5μL of blood is first mixed with deionized (DI) water to lyse the RBC and release Hb content into the solution. Less than 1μL of this is then stamped onto the cellulose acetate paper and an electric field is applied that causes the hemoglobin types to travel different distances across the paper strip. The result can be achieved in as little time as 10 minutes with high sensitivity and specificity among the different hemoglobin types. It is a low-cost assay that has relatively good accuracy and takes very less time to get result. This methodology can be compared in terms of detection and quantification quality with standard HPLC assay and electrophoresis screening methods used in laboratories. The inclusion of mobile devices to analyze the result also makes this device quite practical in terms of its usage at the POC. This device requires a very low power supply, which can be easily substituted with a rechargeable battery for field applications. However, detection of high percentage of HbF in newborns that usually overshadows other Hb types is still a challenge (see Table 1 below). 
Discussion and Conclusions:
Proper screening and early diagnosis of SCD individuals is vital to their management and treatment. Improper screening or a delay results in higher mortality rates among SCD patients. Several SCD screening techniques were developed in the early 1970s.
Unfortunately, many such methodologies proved to be unreliable since they gave false positive or negative results that led to wrong treatment and confusion. In order to IEF is based on the principle that the net charge in the proteins varies based upon the surrounding pH and at their respective isoelectric point (pI) all proteins carry zero charge. Hemoglobin molecules present in the blood samples are thus run in a gel having pH gradient under an electric field and they stop as they reach their respective pI points.
IEF methodology has relatively low cost and has high throughput abilities and thus is the assay-of-choice in many clinical laboratories. In this context a pilot study conducted in Tunisia, Africa has been mentioned here that uses a low cost SCD screening technique by collecting blood samples on blotting paper printed in a common office printer and then analyzing the samples in a laboratory prepared gel for IEF assay (Hajer et al .2012) .
HPLC although being an expensive method for hemoglobinopathy screening is used in many clinical laboratories across developed nations for its accuracy in detection and less time to get result.
An alternative methodology for screening SCD individuals is LC-MS/MS, which is able to detect Hb peptides following digestion of blood spots with trypsin. This is also an extremely accurate and fast method that can be applied for population screening for identification of clinically important globin mutations.
SCD screening can also be achieved by DNA analysis, one of the methodology in this category include RFLP assay, in which β-globin gene is first PCR amplified and then cut with the restriction enzyme DdeI. Absence of this restriction site indicates the presence of mutated β-globin gene since the point mutation eliminates the above restriction site. Whole exome genome sequencing (WES) to look for SNVs in the β-globin gene is also currently followed by several laboratories although sequencing is an expensive technology and only developed nations can afford it.
The review also explains the emerging POC methodologies that are developed considering the cost factor at a certain location, trained technicians available and accessibility. Four such emerging methodologies have been discussed here that are as follows, a) paper-based hemoglobin assays, b) lateral flow immunoassays, c) densitybased separation, and d) micro engineered electrophoresis (HemeChip).
The paper-based hemoglobin assay takes utilizes capillary action of blood sample when applied to a paper-based device called μPADs that causes different hemoglobin types of form unique patterns that can be easily distinguished from one another.
The lateral flow immunoassay comprises of a test strip that has polyclonal antibodies against different hemoglobin types conjugated with colored nanoparticles. An antigenantibody complex is formed between respective hemoglobins once the blood sample reaches the lines in the strip.
Density-based separation has an AMPS comprising of two and three phases that uses cell density measurements to detect RBC. Blood samples are centrifuged in capillary tubes and SCD cells that are of higher density settle at the lowest interphase.
The micro engineered electrophoresis (HemeChip) consists of a cellulose acetate paper housed inside a PMMA chamber where sample blood electrophoresis is conducted to separate different hemoglobin types. A mobile-based application software can be used that is compatible with this assay to process image.
Most of these emerging methodologies are able to distinguish between HbA, HbA2, HbS, HbF and HbF hemoglobin types. These emerging methodologies are based on resources that are easily available at the POC of even economically challenged nations.
The advantages and disadvantages of each methodology for screening of SCD have been discussed in this review. However, considering every factor that includes overall cost, practicality of using an assay in both developed and developing nations, available resources to perform the test, sensitivity, specificity, different Hb variants that can be identified with certainty, the methodology-of-choice would be Lateral Flow immunoassay (Sickle SCAN and HemoTypeSC). This methodology is categorized as a
